Introduction
Calcium-activated chloride channels (CACCs) underpin various physiological activities including smooth muscle contraction, secretion, neuronal firing, and cardiomyocyte depolarization. Study of CACCs has always been plagued by the molecular identity being unknown, 1 the lack of truly selective tools 2 and the complicated interaction of so called chloride channel blockers with native CACCs. 2 -5 Recent work has revealed a remarkable pharmacological overlap between calcium-activated chloride currents (I ClCa ) and the large conductance, calcium-activated potassium channel (BK Ca or K Ca 1.1). 2 Thus, a wide range of structurally disparate agents considered to be chloride channel blockers, such as niflumic acid (NFA), anthracene-9-carboxylate (A-9-C) and ethacrynic acid, enhance K Ca 1.1 currents. 6 -8 Furthermore, in vascular myocytes, the structurally different activators of K Ca 1.1 channels, NS1619 and isopimaric acid, augment I ClCa , 9 and the K Ca 1.1 blockers paxilline, penitrem A, and iberiotoxin inhibit I ClCa . 10 Moreover, tamoxifen, which blocks I ClCa effectively, 10 either blocks or activates K Ca 1.1 channels depending on the presence of a b-auxiliary subunit. 11 In contrast, positive and negative modulators of small and intermediate conductance, Ca 2+ -activated K + channels (K Ca 2.1 and K Ca 2.3) do not affect I ClCa . 10 These observations led to the postulate that CACCs and K Ca 1.1 contained a common structural motif or co-existed in a sufficiently narrow micro-domain to allow inter-channel activity. 2 Much evidence is now available for the compartmentalization of protein complexes into highly organized cholesterol-and sphingolipid-enriched structures within the plasma membrane, termed lipid rafts. 12 These moieties selectively include, but also exclude, certain proteins from macromolecular complexes in order to aid efficient signalling and trafficking. The presence of the protein caveolin (isoforms: 1-3) in these specialized lipid-rich domains results in the formation of caveolae, a subtype of lipid raft, that form membrane invaginations of 50-100 nm in diameter that can be visualized by electron microscopy. K Ca 1.1 channels have been shown to localize to lipid rafts within cell membranes 13, 14 and surface expression and conductance of K Ca 1.1 channels are modulated by interaction with caveolin-1 protein. 15 Treatment of cells with cholesterol depleting agents, such as methyl-b-cyclodextrin (M-bCD), modulates K Ca 1.1 channel currents. 14, 16 The present study aimed to assess whether M-bCD affected the biophysical and pharmacological properties of CACCs. The data presented suggest that CACCs are present in lipid sub-domains. More strikingly, this study reveals that the distinctive pharmacology of CACCs relies upon intact lipid rafts. Overall, these data lend weight to the possibility that native CACCs exist as part of a multi-protein complex.
Methods
For detailed Methods see Supplementary material online, Methods. 
Tissue collection

Cell dissociation
Individual smooth muscle myocytes were isolated from strips of mouse portal vein (PV) by incubation at 378C for 20 min with 1.5 mg mL 21 collagenase XI followed by 10 min with 1 mg mL 21 protease XIV, followed by gentle trituration with a wide bore fire polished pipette.
Electrophysiology
Macroscopic I ClCa were recorded from a total of 85 cells from 46 different mice using pipette solutions containing 106 mM CsCl, 20 mM TEA, 3 mM Na 2 ATP, 0.2 mM GTP-Na, 10 mM HEPES, 10 mM BAPTA, ) from 2100 to +100 mV every 15 s. All experiments were performed at room temperature.
Cholesterol modifying agents
Once I ClCa had stabilized the role of lipid rafts was determined by application of M-bCD (0.03-3 mg mL 21 ), a cholesterol chelating agent which enhances aqueous solubility of cholesterol, as described previously. 20 -23 M-bCD pre-bound to cholesterol was used to rule out possible cholesterol independent effects. 20 
Lipid raft isolation
Portal veins (PV) from 30 mice were crushed in liquid nitrogen and homogenized in 1 ml lysis buffer (Sigma-Aldrich; Poole, UK) containing 1% Triton X-100. One half of the total lysate was incubated with 3 mg mL 21 M-bCD for 15 min, whereas the other half was incubated with the appropriate vehicle. Both lysates were fractionated using the Caveolae/Raft Isolation Kit (Sigma-Aldrich). A discontinuous sucrose gradient (0 -40%) was constructed using different volumes of OptiPrep and centrifuged at 200 000 g for 4 h at 48C. After centrifugation, 12 fractions of 1 mL were collected from the top (fraction 1) to the bottom (fraction 12) of the tube and stored at 2208C until required for western blot analysis.
Western blots
Protein samples were denatured at 958C for 5 min in the presence of reducing agent (Invitrogen, UK), loaded onto a pre-cast sodium dodecyl sulphate-polyacrylamide gel (4 -12% Bis-Tris, Invitrogen, UK), subjected to electrophoresis and then transferred onto PVDF membranes (Amersham Biosciences). The membranes were then probed for the lipid raft marker proteins caveolin (pan-caveolin 24 1:10 000; BD Biosciences) and flotillin-2 25 (1:20 000; BD Biosciences), the non-lipid raft protein marker b-adaptin 26 (1:1500; Santa Cruz), K Ca 1.1 (1:200; Alomone), and TMEM16A (ab53213; Abcam; a 1:5 dilution of a prediluted form). Protein bands were visualized using ECL (Thermo Scientific) and hyperfilm (Amersham Bioscience). All antibodies had been tested to determine effective concentrations and non-specific effects on samples of whole heart and whole PV in previous experiments (data not shown). Owing to low levels of protein, SignalBoost Immunoreaction Enhancer (Calbiochem; Nottingham, UK) was used with the anti-flotillin-2 antibody; it was not suitable/required for use with the other antibodies used in this investigation.
Statistical analysis
All data are means + SEM taken from at least three animals. Statistical comparison was performed between the stable response observed prior to exposure to modulators (t ¼ 0) and that obtained in the presence of modulators using either paired Student's t-test or ANOVA. All drugs were purchased from Sigma-Aldrich unless otherwise indicated.
Results
I ClCa evoked by pipette solutions containing 500 nM free Ca 2+ exhibited a rapid rundown immediately after membrane rupture and then remained constant for the duration of the experiment. At 250 mV, the mean inward current was 21.6 + 0.2 pA pF 21 (n ¼ 7) and depolarization to +70 mV yielded currents with distinctive outward kinetics ( Figure 1A ) that are characteristic of I ClCa recorded by this technique. 9,10,17 -19 The current at +70 mV increased from a mean level of 2. 
Effect of M-bCD on native Ca 21 -activated Cl 2 currents in mPV myocytes
Application of M-bCD (3 mg mL 21 ) rapidly augmented I ClCa ( Figure 1A ) with half maximal enhancement (t 0.5 ) occurring after 1.8 min ( Figure 1D ). Figure 1B shows that augmentation of I ClCa was
Vascular chloride channels and lipid rafts also observed with 0.3 mg mL 21 M-bCD but not lower concentrations (0.03-0.1 mg mL
21
, n ≥ 3). In contrast, application of 3 mg mL 21 M-bCD pre-bound with an equivalent concentration of cholesterol did not produce any changes in I ClCa that were significant from vehicle effects (n ¼ 6; Figure 1D and E). Application of 3 mg mL 21 M-bCD increased the current at 250 mV from 21.6 + 0.2 pA pF 21 to 21.9 + 0.3 pA pF 21 (n ¼ 7; P , 0.05) and at all test potentials ( Figure 1E , significance only at +120 mV shown for clarity). Maximal extrapolated whole-cell conductance increased from 21.1 to 27.8 nS, whereas V 0.5 decreased from 113 to 93 mV ( Figure 1F ). The stimulatory effects of M-bCD were not reversed upon removal from the bath solution for up to 15 min (n ¼ 3). The augmentation of I ClCa was not due to the de novo recruitment of a new ionic conductance as neither the reversal potential ( Figure 1G ) nor the kinetics at +70 or 280 mV were affected by M-bCD. These data are the first to show that Ca 2+ -activated Cl 2 currents are affected by cholesterol depletion.
Effect of M-bCD on native Ca 21 -activated K 1 currents in mPV myocytes
Experiments were performed to see if M-bCD also modulated large conductance K Ca 1.1 currents in mPV myocytes similar to previous findings in uterine smooth muscles cells and gliomas. 14, 16 As Figure 2A shows application of a depolarizing voltage ramp with pipette solutions containing [Ca 2+ ] fixed at 250 nM evoked an outwardly rectifying I K superimposed by considerable current fluctuations at positive potentials that was inhibited by the K Ca 1.1 channel blocker 1 mM paxilline 27, 28 by 80 + 2% (P , 0.05; n ¼ 4). Application of M-bCD (3 mg mL
21
) reduced I K (Figure 2A and B) with a time course similar to the effect on I ClCa (t 0.5 ¼ 2.7 min, Figure 2C ), which was not manifest in cells pre-treated with paxilline ( Figure 2B ). The effect of M-bCD on I K was also maintained after washout of the cyclodextrin (n ¼ 3). Thus, K Ca 1.1 channels in vascular myocytes are inhibited by cholesterol depletion. and A-9-C to assess whether disruption of cholesterol levels affected the ability of these chloride channel blockers to modify I ClCa . In vascular myocytes, these agents produce complex effects on sustained I ClCa , which is manifest as a significant but not complete inhibition at positive potentials and a paradoxical stimulation of I ClCa at negative potentials. 3 -5,9 Figure 3 shows that NFA (100 mM) produced effects, comparable to those observed previously in mPV myocytes by increasing holding current at 250 mV, inhibiting late outward current and increasing inward current upon repolarization to 280 mV (n ¼ 4; Figure 3Ai ). Similar effects were observed in the presence of M-bCD (Figure 3Aii ). In the absence of M-bCD, NFA evoked a decrease in the outward time-dependent current of 2.6 + 1.3 pA pF 21 , whereas in the presence of M-bCD, a decrease of 3.9 + 0.8 pA pF 21 was observed. In addition, the inward current at 280 mV in the presence of NFA was larger in M-bCD (Figure 3Aiii ). Both observations reflect a heightened activation of the underlying CACCs. Application of A-9-C (500 mM) produced effects similar to those previously reported in the rabbit pulmonary artery 4 that were manifest as a reduction in current at +70 mV and a marked augmentation of the current recorded upon repolarization to 280 mV (n ¼ 3; Figure 3Bi ), which were also apparent after application of 3 mg mL 21 M-bCD (n ¼ 4; Figure 3Bii ). However, the enhancement of the current at 280 mV produced by A-9-C increased from 6.1 + 1.2 to 8.8 + 3.8 pA pF 21 in M-bCD (n ¼ 4, Figure 3Biii ) again consistent with an increase in the availability of the underlying CACC. These data show that the distinctive bimodal effects of NFA and A-9-C on sustained I ClCa were maintained after incubation with M-bCD.
Effects of K Ca 1.1 modulators on I ClCa in the presence of M-bCD
We have recently shown that the K Ca 1.1 inhibitor paxilline and the K Ca 1.1 activator NS1619 modulate I ClCa . 9, 10 The observation, in the present study, that I ClCa , as well as K Ca 1.1 current, are affected by M-bCD suggests that the pharmacological cross over could stem from a close physical interaction between the Cl 2 channel and K Ca 1.1 in the same microdomain. Consequently, disruption of the local environment by M-bCD might alter the ability of K Ca 1.1 channel modulators to affect I ClCa . Similar to our previous report, 10 1 mM paxilline reduced I ClCa markedly at all potentials but did not affect the reversal potential of the evoked current (n ¼ 4, Figure 4Ai -Aiii). In stark contrast, paxilline had no effect on I ClCa in the presence of M-bCD (3 mg mL 21 ; n ¼ 4; Figure 4Bi -Biii). Moreover, as Figure 4C shows addition of M-bCD (3 mg mL 21 ) reversed completely the inhibition of I ClCa produced by paxilline with a time course similar to the stimulatory effect of M-bCD alone (t ¼ 2.1 min, Figure 4Civ , n ¼ 4). M-bCD did not reverse the inhibitory effect of paxilline on I K (n ¼ 3). Similarly tamoxifen (10 mM), another K Ca 1.1 modulator, which inhibits I ClCa 10 (n ¼ 4), induced no change in I ClCa after pre-incubation with M-bCD (3 mg mL 21 ; n ¼ 4; Figure 5A and B). The presence of M-bCD also limited the stimulatory effect of the K Ca 1.1 channel activator NS1619 on I ClCa ( Figure 5C and D). Figure 5C shows that similar to Saleh et al. 9 Thirty micromolar NS1619 increased I ClCa at all potentials with the current at the end of a 750 ms step to +70 mV increasing from 7.7 + 2.1 to 16.9 + 2.9 pA pF 21 (P , 0.05, n ¼ 4). In contrast, I ClCa was unaffected by the application of 30 mM NS1619 when the myocytes had been previously treated with M-bCD (3 mg mL
21
; n ¼ 4; Figure 5D ). These data provide evidence that the effects of K Ca 1.1 modulators on I ClCa are reliant upon functional lipid microdomains.
Lipid fractionation studies
In the present study, electrophysiological effects were observed with a relatively mild treatment with M-bCD compared with previous studies where higher concentrations (5-10 mg mL 21 ) and longer application times (1-3 h) have been used. 22, 23, 25, 26 Thus, a series of experiments were undertaken to assess whether the M-bCD treatment used in the electrophysiology studies could affect the distribution of lipid raft markers. Figure 6A shows representative western blot analysis following discontinuous sucrose density ultracentrifugation of mPV tissue. Immunodetection with antibodies directed against b-adaptin and caveolin produced a localization profile similar to previous work in rat aorta. 23, 26 The localization pattern for flotillin-2 was also consistent with earlier work when the same concentration of Triton-X (1%) was used, indicating that flotillin-2-enriched lipid rafts are susceptible to glycerophospholipid depletion. 25 Treatment of the protein lysate for 15 min incubation with M-bCD (3 mg mL 21 ) produced an obvious reduction in density of the bands for caveolin and flotillin-2 at lower fractions and the appearance of bands in later fractions ( Figure 6A ). The non-raft marker b-adaptin was affected considerably less by incubation with M-bCD ( Figure 6A ). These data show that the electrophysiological effects of M-bCD are associated with changes in the buoyancy of lipid raft markers. The molecular identity of CACCs is unknown but recently the gene TMEM16A has been proposed as a strong candidate for this channel. 29 -31 Consequently, we ascertained whether TMEM16A could be detected in mPV lysates and whether it existed in the same lipid fractions as K Ca 1.1. Figure 6B shows that TMEM16A and K Ca 1.1 immunoreactivity was detected in PV lysates. K Ca 1.1 staining appeared most abundant in fractions that overlapped with caveolin and not with b-adaptin, suggesting that this ion channel may be located in the caveolae fraction of lipid rafts similar to other smooth muscles. TMEM16A staining was apparent in some of the same fractions as K Ca 1.1 but was generally present in less buoyant fractions ( Figure 6B ). Treatment with M-bCD caused a small, but obvious shift in the appearance of TMEM16A and K Ca 1.1 to less buoyant fractions.
Discussion
The work of the present study shows that the amplitude and pharmacology of CACCs in vascular smooth muscle cells is drastically altered by short application of M-bCD, an agent shown to deplete cholesterol levels. Western blot analysis after sucrose gradient Vascular chloride channels and lipid rafts ultracentrifugation showed that lipid raft markers caveolin and flotillin-2 migrated to less buoyant fractions upon treatment with M-bCD. This agent had no effect on the non-raft marker b-adaptin but had a subtle effect on the staining pattern for K Ca 1. 35 The present study shows that a brief application of M-bCD, at relatively low concentrations (3 mg mL
21
) compared with previous studies, 22 -26 also reduced macroscopic paxilline-sensitive K + currents in PV myocytes. Importantly, the present study also shows that the same low concentration of M-bCD increased the amplitude of I ClCa with the same, rapid time course as the effect on K + currents and caused translocation of the lipid raft markers caveolin and flotillin-2 to less buoyant fractions.
No stimulation of I ClCa was observed when M-bCD had been preincubated with cholesterol showing that the effect on I ClCa was due to cholesterol depletion rather than an effect of the cyclodextrin itself. The similar time course of the effect of M-bCD on I K and I ClCa suggests a common biochemical event is involved, although this may represent a subtle alteration in the macromolecular complex rather than complete disruption of the lipid raft. An even more striking observation was that cholesterol depletion by M-bCD abolished the effect of agents known to modulate K Ca 1.1 channels on I ClCa . Hence, the selective K Ca 1.1 blocker paxilline, which abolishes I ClCa at all voltages in mPV myocytes 10 and in the present study, was totally ineffective in the presence of M-bCD. Similarly, tamoxifen, which activates or inhibits K Ca 1.1 depending on the presence of an auxiliary subunit, 11 abolished I ClCa in the absence but not in the presence of M-bCD 10 and in the present study. Moreover, the K Ca 1.1 opener NS1619, shown to enhance I ClCa in vascular myocytes, 9 had no effect on I ClCa in the presence of M-bCD. This inability to augment I ClCa was not due to M-bCD increasing the current to saturating levels, because Saleh et al. 9 showed that NS1619 augmented I ClCa generated by a higher activating [Ca 2+ ]
(1 mM vs. 500 nM). In contrast, the bimodal inhibition and stimulation of I ClCa reported for the so-called Cl 2 channel blockers NFA and A-9-C 3 -5 were generally unaffected by M-bCD, although the stimulatory effect of these agents was greater in M-bCD. This reflects a greater availability of the underlying CACCs and may be related to the impact of phosphorylation on the pharmacology of Ca 2+ -activated Cl 2 channels shown recently. 36 Overall, the present data provide support for K Ca 1.1 and Ca 2+ -activated Cl 2 channel proteins existing in a restricted space to allow pharmacological overlap. Disruption of cholesterol by M-bCD uncouples these two proteins and causes the loss of the pharmacological overlap.
It is tempting to speculate that the native Ca 2+ -activated Cl 2 channel exists as a multimeric assemblage consisting of a pore forming subunit, possibly TMEM16A after recent publications 29 -31 and the expression data of the present study, K Ca 1.1 and various signalling moieties such as CaMKII, calcineurin, and PP1 known to regulate vascular I ClCa . 1, 18, 19, 37 However, the sucrose gradient work of the present study suggests that TMEM16A is distributed more evenly in the plasma membrane rather than just localized in rafts, even though some overlap with caveolin was observed and the pattern of TMEM16A staining was altered by mild treatment with M-bCD. These data suggest that if TMEM16A constitutes the native CACCs in smooth muscle then the nature of any molecular interaction with K Ca 1.1 is more subtle or complex than simple consolidation in a discrete microdomain. Ongoing experiments are aimed at ascertaining whether TMEM16A expression products contribute to native CACCs in smooth muscle.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
